Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virchows Archiv
Published in: Virchows Archiv 3/2017

01-03-2017 | Invited Review

Medication-associated gastrointestinal tract injury

Authors: Michael Vieth, Elizabeth Montgomery

Published in: Virchows Archiv | Issue 3/2017

Login to get access

Abstract

Medication-associated gastrointestinal (GI) tract injury has been known for centuries for some medications. The more recently introduced biologicals are a class of drugs that constantly increases, and as such, the spectrum of GI tract side effects is steadily growing. This review covers not only long-known GI tract side effects of drugs but also those more recently described. A comprehensive but concise list of medications used in daily practice and associated with GI tract injury is presented.
Literature
1.
Paracelsus, von Hohenheim PAT (1574) Septem Defensiones. Basel
2.
Douthwaite A, Lintott G (1938) Gastrosopic observation of the effect of aspirin and other substances on the stomach. The Lancet 232:1222–1224CrossRef
3.
4.
Walker NI, Bennett RE, Axelsen RA (1988) Melanosis coli. A consequence of anthraquinone-induced apoptosis of colonic epithelial cells. The American journal of pathology 131:465–476PubMedPubMedCentral
5.
6.
Piccone VA, Klopstock R, LeVeen HH, Sika J (1970) Primary malignant melanoma of the esophagus associated with melanosis of the entire esophagus. First case report. The Journal of thoracic and cardiovascular surgery 59:864-870
7.
8.
9.
10.
11.
Johnson JE, Carpenter BL, Benton J, Cross R, Eaton LA Jr, Rhoads JM (1991) Hemorrhagic colitis and pseudomelanosis coli in ipecac ingestion by proxy. Journal of pediatric gastroenterology and nutrition 12:501–506CrossRefPubMed
12.
Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, Masclee AA (2010) Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Alimentary pharmacology & therapeutics 32:1124–1128. doi:10.​1111/​j.​1365-2036.​2010.​04453.​x CrossRef
13.
14.
Logan RP (1996) The chemotherapeutic effects of H+/K+ inhibitors on Helicobacter pylori infection. Pharmacology & therapeutics 69:79–83CrossRef
15.
Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH (1995) Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36:12–16CrossRefPubMedPubMedCentral
16.
Stolte M, Bethke B, Ruhl G, Ritter M (1992) Omeprazole-induced pseudohypertrophy of gastric parietal cells. Zeitschrift fur Gastroenterologie 30:134–138PubMed
17.
Lundell L, Attwood S, Ell C, Fiocca R, Galmiche JP, Hatlebakk J, Lind T, Junghard O, collaborators Lt (2008) Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 57:1207–1213. doi:10.​1136/​gut.​2008.​148833 CrossRefPubMedPubMedCentral
18.
Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ (2015) Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Alimentary pharmacology & therapeutics 42:649–663. doi:10.​1111/​apt.​13324 CrossRef
19.
Haratake J, Yasunaga C, Ootani A, Shimajiri S, Matsuyama A, Hisaoka M (2015) Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. The American journal of surgical pathology 39:767–771. doi:10.​1097/​PAS.​0000000000000385​ CrossRefPubMed
20.
Khurram M, Montgomery E (2015) Lanthanum carbonate-associated injury to the small intestine. Diagnostic Histopathology 21:452–454CrossRef
21.
22.
23.
Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C (2011) Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial AJR. American journal of roentgenology 197:W562–W570. doi:10.​2214/​AJR.​10.​4379 CrossRefPubMed
24.
Abraham SC, Yardley JH, Wu TT (1999) Erosive injury to the upper gastrointestinal tract in patients receiving iron medication: an underrecognized entity. The American journal of surgical pathology. 23:1241–1247CrossRefPubMed
25.
26.
27.
Eckstein RP, Symons P (1996) Iron tablets cause histopathologically distinctive lesions in mucosal biopsies of the stomach and esophagus. Pathology 28:142–145CrossRefPubMed
28.
29.
Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. The American journal of surgical pathology 20:1161–1181CrossRefPubMed
30.
Goldstein NS, Cinenza AN (1998) The histopathology of nonsteroidal anti-inflammatory drug-associated colitis. American journal of clinical pathology 110:622–628CrossRefPubMed
31.
Cortina G, Wren S, Armstrong B, Lewin K, Fajardo L (1999) Clinical and pathologic overlap in nonsteroidal anti-inflammatory drug-related small bowel diaphragm disease and the neuromuscular and vascular hamartoma of the small bowel. The American journal of surgical pathology 23:1414–1417CrossRefPubMed
32.
33.
Daniels JA, Gibson MK, Xu L, Sun S, Canto MI, Heath E, Wang J, Brock M, Montgomery E (2008) Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect. The American journal of surgical pathology 32:473–477. doi:10.​1097/​PAS.​0b013e3181582331​ CrossRefPubMed
34.
Hruban RH, Yardley JH, Donehower RC, Boitnott JK (1989) Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63:1944–1950CrossRefPubMed
35.
Iacobuzio-Donahue CA, Lee EL, Abraham SC, Yardley JH, Wu TT (2001) Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. The American journal of surgical pathology 25:1067–1073CrossRefPubMed
36.
37.
38.
Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A 3rd, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. International journal of radiation oncology, biology, physics 68:13–23. doi:10.​1016/​j.​ijrobp.​2006.​11.​060 CrossRefPubMed
39.
40.
Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, Murthy R, Ryu RK, Sato KT, Miller FH, Omary RA, Salem R (2008) Biliary sequelae following radioembolization with yttrium-90 microspheres. Journal of vascular and interventional radiology : JVIR. 19:691–697. doi:10.​1016/​j.​jvir.​2008.​01.​003 CrossRefPubMed
41.
Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W, Cohen AM, Censullo M (2007) Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. Journal of vascular and interventional radiology : JVIR 18:553–561 . doi:10.​1016/​j.​jvir.​2007.​02.​002quiz 562CrossRefPubMed
42.
43.
44.
45.
Abraham SC, Bhagavan BS, Lee LA, Rashid A, Wu TT (2001) Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. The American journal of surgical pathology. 25:637–644CrossRefPubMed
46.
Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM (2013) Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. The American journal of medicine 126(264):e269–e224. doi:10.​1016/​j.​amjmed.​2012.​08.​016
47.
Lillemoe KD, Romolo JL, Hamilton SR, Pennington LR, Burdick JF, Williams GM (1987) Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery 101:267–272PubMed
48.
Rashid A, Hamilton SR (1997) Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. The American journal of surgical pathology 21:60–69CrossRefPubMed
49.
50.
Arnold MA, Swanson BJ, Crowder CD, Frankel WL, Lam-Himlin D, Singhi AD, Stanich PP, Arnold CA (2014) Colesevelam and colestipol: novel medication resins in the gastrointestinal tract. The American journal of surgical pathology. 38:1530–1537. doi:10.​1097/​PAS.​0000000000000260​ CrossRefPubMed
51.
Swanson BJ, Limketkai BN, Liu TC, Montgomery E, Nazari K, Park JY, Santangelo WC, Torbenson MS, Voltaggio L, Yearsley MM, Arnold CA (2013) Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury. The American journal of surgical pathology 37:1686–1693. doi:10.​1097/​PAS.​0b013e3182999d8d​ CrossRefPubMed
52.
53.
Antar A, Ishak RS, Otrock ZK, El-Majzoub N, Ghosn S, Mahfouz R, Taher AT (2014) Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. Hematology/oncology and stem cell therapy. 7:166–169. doi:10.​1016/​j.​hemonc.​2014.​09.​008 CrossRefPubMed
54.
55.
56.
Papadimitriou JC, Cangro CB, Lustberg A, Khaled A, Nogueira J, Wiland A, Ramos E, Klassen DK, Drachenberg CB (2003) Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. International journal of surgical pathology 11:295–302CrossRefPubMed
57.
Papadimitriou JC, Drachenberg CB, Beskow CO, Cangro C, Wiland A, Klassen D, Weir M, Bartlett S (2001) Graft-versus-host disease-like features in mycophenolate mofetil-related colitis. Transplantation proceedings 33:2237–2238CrossRefPubMed
58.
59.
60.
61.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine 363:711–723. doi:10.​1056/​NEJMoa1003466 CrossRefPubMedPubMedCentral
62.
Khoja L, Atenafu EG, Ye Q, Gedye C, Chappell M, Hogg D, Butler MO, Joshua AM (2016) Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncology letters 11:1581–1585. doi:10.​3892/​ol.​2015.​4069 PubMed
63.
Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY (2008) Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. The American journal of surgical pathology 32:1130–1137. doi:10.​1097/​PAS.​0b013e31817150e3​ CrossRefPubMed
64.
Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, Doyle LA (2015) Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. The American journal of surgical pathology 39:1075–1084. doi:10.​1097/​PAS.​0000000000000453​ CrossRefPubMed
65.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. The New England journal of medicine 372:2018–2028. doi:10.​1056/​NEJMoa1501824 CrossRefPubMed
66.
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA (2016) PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. The New England journal of medicine 374:2542–2552. doi:10.​1056/​NEJMoa1603702 CrossRefPubMedPubMedCentral
67.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A (2015) Pembrolizumab versus ipilimumab in advanced melanoma. The New England journal of medicine 372:2521–2532. doi:10.​1056/​NEJMoa1503093 CrossRefPubMed
68.
69.
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. The New England journal of medicine 369:122–133. doi:10.​1056/​NEJMoa1302369 CrossRefPubMed
70.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr (2015) PD-1 blockade in tumors with mismatch-repair deficiency. The New England journal of medicine 372:2509–2520. doi:10.​1056/​NEJMoa1500596 CrossRefPubMedPubMedCentral
71.
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O’Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology 16:908–918. doi:10.​1016/​S1470-2045(15)00083-2 CrossRefPubMed
72.
Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ (2016) Fulminant myocarditis with combination immune checkpoint blockade. The New England journal of medicine 375:1749–1755. doi:10.​1056/​NEJMoa1609214 CrossRefPubMed
73.
Postow MA (2015) Managing immune checkpoint-blocking antibody side effects American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting:76-83. doi: 10.​14694/​EdBook_​AM.​2015.​35.​76
74.
75.
Blombery P, Prince HM, Levinson M, Pianko S, Maxwell E, Bhathal P (2011) Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29:e110–e112. doi:10.​1200/​JCO.​2010.​31.​8899 CrossRef
76.
Lipka S, Katz S, Crawford JM (2016) Fulminant colitis following rituximab. Therapy Gastroenterology & hepatology 12:58–60
77.
Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H (2013) Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. The American journal of surgical pathology 37:563–570. doi:10.​1097/​PAS.​0b013e3182759008​ CrossRefPubMed
78.
79.
Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA (2015) Idelalisib-associated enterocolitis: clinicopathologic features and distinction from other enterocolitides. The American journal of surgical pathology 39:1653–1660. doi:10.​1097/​PAS.​0000000000000525​ CrossRefPubMed
80.
81.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. The New England journal of medicine 372:621–630. doi:10.​1056/​NEJMoa1406470 CrossRefPubMed
82.
83.
84.
Lagana SM, Braunstein ED, Arguelles-Grande C, Bhagat G, Green PH, Lebwohl B (2015) Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers. Journal of clinical pathology 68:29–32. doi:10.​1136/​jclinpath-2014-202615 CrossRefPubMed
85.
Choi EY, McKenna BJ (2015) Olmesartan-associated enteropathy: a review of clinical and Histologic findings Archives of pathology & laboratory medicine 139:1242-1247. doi: 10.​5858/​arpa.​2015-0204-RA
86.
Marietta EV, Nadeau AM, Cartee AK, Singh I, Rishi A, Choung RS, Wu TT, Rubio-Tapia A, Murray JA (2015) Immunopathogenesis of olmesartan-associated enteropathy. Alimentary pharmacology & therapeutics 42:1303–1314. doi:10.​1111/​apt.​13413 CrossRef
87.
88.
Akram S, Murray JA, Pardi DS, Alexander GL, Schaffner JA, Russo PA, Abraham SC (2007) Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 5:1282–1290 . doi:10.​1016/​j.​cgh.​2007.​05.​013quiz 1245CrossRef
89.
Daniels JA, Lederman HM, Maitra A, Montgomery EA (2007) Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. The American journal of surgical pathology 31:1800–1812. doi:10.​1097/​PAS.​0b013e3180cab60c​ CrossRefPubMed
90.
91.
92.
Dejaco C, Oesterreicher C, Angelberger S, Puspok A, Birner P, Poetzi R, Gangl A, Oberhuber G (2003) Diagnosing colitis: a prospective study on essential parameters for reaching a diagnosis. Endoscopy 35:1004–1008. doi:10.​1055/​s-2003-44593 CrossRefPubMed
Metadata
Title
Medication-associated gastrointestinal tract injury
Authors
Michael Vieth
Elizabeth Montgomery
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 3/2017
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-017-2077-3

Other articles of this Issue 3/2017

Virchows Archiv 3/2017 Go to the issue

Original Article

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival

Original Article

Glycine decarboxylase and HIF-1α expression are negative prognostic factors in primary resected early-stage non-small cell lung cancer

News

In this issue

Original Article

Actin isoform expression patterns in adult extracardiac and cardiac rhabdomyomas indicate a different cell of origin

Original Article

Molecular characterization of CD44+/CD24−/Ck+/CD45− cells in benign and malignant breast lesions

Book Review

Book Review—Hematopathology, 2nd edition